molecules of the month


oral prostaglandin F receptor GCPR antagonist

to treat IPF, in vivo efficacy in fibrosis model

from ~3M cmpd cell-based HTS and opt.

J. Med. Chem., Oct. 22, 2020 issue

Bayer AG, Wuppertal, DE

Structure of BAY-6672, a potent, selective and orally bioavailable prostanoid FP receptor antagonist
1 min read

BAY-6672 (Bayer oral in vivo prostaglandin F receptor GCPR antagonist)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: